According to a report from the CDC, RSV infection poses a significant risk to this age group, often leading to severe respiratory illness, hospitalization, and death.

Babies exposed to maternal RSV (respiratory syncytial virus) vaccination in the third trimester are not at an increased risk of preterm birth or other poor birth outcomes, according to a study today in JAMA Network Open.

Pfizer's respiratory syncytial virus (RSV) vaccine for pregnant women was not tied to a higher risk of pre-term or early births, according to a study published on Monday that analyzed real-world use of the shots.

It found that getting the shot during late pregnancy was not associated with increased odds of preterm birth or other outcomes. The difference in preterm birth rates between vaccinated women (5.9%) and unvaccinated women (6.